A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Pharmacology research & perspectives|2022|Langeskov E, Kristensen K|9 citations
Semaglutide is a glucagon-like-peptide-1 (GLP-1) analogue marketed for once-weekly subcutaneous administration for type 2 diabetes mellitus. Like other long-acting GLP-1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rat…
PMID: 35799471
Cardiovascular endocrinology & metabolism|2022|Qureshy K et al.
We assessed physicians' experiences of prescribing once-weekly (OW) semaglutide to patients with type 2 diabetes (T2D) in Canada. Physicians who had prescribed OW semaglutide to ≥2 patients with T2D in the past 12 months and had been doing so for ≥3…
PMID: 35350598
Current opinion in endocrinology, diabetes, and obesity|2022|Mathiesen D, Bagger J, Knop F|34 citations
PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight…
Review
PMID: 35066542
BMC endocrine disorders|2022|Qin J, Song L|23 citations
BACKGROUND: The cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists are still controversial in the treatment of type 2 diabetes mellitus (T2DM) patients. The purpose of this study was to evaluate the risk of cardiovascular eve…
Meta-Analysis
PMID: 35546664
Journal of inflammation research|2022|Pan X et al.|17 citations
PURPOSE: Using proteomics to study the effect of semaglutide on cardiac protein expression in obese mice. Assessment of the effect of semaglutide on cardiac function in obese mice. MATERIALS AND METHODS: The mice were randomly divided into three grou…
Animal Study
PMID: 36452054
Frontiers in neurology|2022|Cao Y et al.|17 citations
Alzheimer's disease is the most common neurodegenerative disease. Prior to 2017, National Medical Products Administration approved only four drugs to treat Alzheimer's disease, including three cholinesterase inhibitors and one N-methyl-D-aspartate re…
Review
PMID: 36457865
Molecular metabolism|2022|Zimmermann T et al.|101 citations
OBJECTIVE: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activates the glucagon re…
Animal Study
PMID: 36356832
Hormones (Athens, Greece)|2022|Polyzos S, Katsiki N|7 citations
PMID: 35668318
General hospital psychiatry|2022|Lee K, Abraham S, Cleaver R|30 citations
BACKGROUND: Schizophrenia and antipsychotic use are associated with clinically significant weight gain and subsequent increased mortality. Despite weight loss medications (WLMs) licensed by regulatory bodies (FDA, EMA, and MHRA) being available, curr…
Review
PMID: 35863294
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians|2022|Fornes A et al.|22 citations
To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for chronic weight management.A literature search of PubMed/MEDLINE and Google Scholar was performed using the search terms: semaglutide 2.4,…
Review
PMID: 35832567
Biomedicines|2022|Bulum T|17 citations
Diabetes mellitus is the leading cause of chronic kidney disease, and about 30-40% of patients with diabetes will develop kidney disease. Incretin hormones have received attention during the past three decades not only as a pharmacotherapy for the tr…
Review
PMID: 36289848
Annals of internal medicine|2022|Kauffman R|6 citations
Rubino DM, Greenway FL, Khalid U, et al.JAMA. 2022;327:138-50. 35015037.
PMID: 35500264
Journal of endocrinological investigation|2022|Formoso G, Baroni M
PMID: 35524036
The Medical letter on drugs and therapeutics|2022|Unknown authors
PMID: 36384763
Clinical and translational science|2022|Møllerhøj M et al.|58 citations
Non-alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health because of high global prevalence and lack of evidence-based therapies. Most animal models of NASH lack sufficient validation regarding disease progression and ph…
Animal Study
PMID: 35143711
Nutrition, metabolism, and cardiovascular diseases : NMCD|2022|Pennisi G et al.|17 citations
BACKGROUND: The aims of this study were to quantify the histological improvement and its risk factors in patients with NASH enrolled in the placebo arms of randomized controlled trials (RCTs), and to indirectly compare the effect of several investiga…
PMID: 35970684
Scientific reports|2022|Poupon-Bejuit L et al.|13 citations
Infantile neuroaxonal dystrophy (INAD) is a rare paediatric neurodegenerative condition caused by mutations in the PLA2G6 gene, which is also the causative gene for PARK14-linked young adult-onset dystonia parkinsonism. INAD patients usually die with…
Animal Study
PMID: 35970890
Diabetes therapy : research, treatment and education of diabetes and related disorders|2022|Miyake T et al.|7 citations
INTRODUCTION: Untreated nonalcoholic fatty liver may progress to nonalcoholic steatohepatitis (NASH) and cirrhosis and induce hepatocellular carcinoma and liver failure. Type 2 diabetes mellitus (T2DM), often complicated with nonalcoholic fatty liver…
PMID: 35312970
Diabetes therapy : research, treatment and education of diabetes and related disorders|2022|Yamada H et al.|10 citations
INTRODUCTION: Once-weekly (OW) glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide has been shown to have a more potent glycated hemoglobin (HbA1c)-lowering effect than other oral hypoglycemic agents and existing GLP-1RAs in global randomi…
PMID: 36006593
Human & experimental toxicology|2022|Jiang Z et al.|9 citations
BACKGROUND: As a life-threatening respiratory syndrome, acute lung injury (ALI) is characterized by uncontrollable inflammatory activities. Semaglutide (SEM) has been identified as an effective anti-inflammatory drug in a variety of diseases. This st…
Animal StudyIn Vitro
PMID: 36075570